Premium
An Example of Anti‐Yt a Demonstrating a Change in Its Clinical Significance 1
Author(s) -
AuBuchon J.P.,
Brightman A.,
Anderson H.J.,
Kim B.
Publication year - 1988
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1988.tb05087.x
Subject(s) - red cell , clinical significance , antibody , medicine , autoantibody , subclass , antigen , immunology , andrology
. The clinical significance of some red cell alloantibodies remains in doubt and can best be studied with long‐term 51 Cr survival studies. We report a patient whose IgG anti‐Yt a was initially shown not to shorten the lifespan of 51 Cr‐labeled Yt(a+) red cells. At the time of this study, the subclass of the antibody could not be determined. Twelve weeks after transfusion with 4 units of Yt(a+) red cells, the alloantibody for the first time was demonstrable as IgG1; a repeat radiolabeled red cell survival demonstrated significant shortening of the lifespan of Yt(a+) red cells when they were followed for 7 days. These cells had a marked ‘two‐component’ survival curve. Because the patient also demonstrated autoantibody coating his red cells, the clinical effect of this autoantibody was followed with autologous red cells labeled with 111 In; the survival of autologous red cells was normal throughout these studies. Evaluation of the clinical significance of an alloantibody in a patient may require long‐term 51 Cr red cell survival studies and repetition of these studies after exposure to large quantities of the antigen.